Men's Health News

RSS

High Intensity Focused Ultrasound treatment now available in the U.S. to treat prostate cancer

A minimally-invasive treatment just became available to men suffering from prostate cancer in the United States. After more than 10 years of clinical trials, the Food and Drug Administration on October 9 approved the use of High Intensity Focused Ultrasound (HIFU), a procedure that can zero in on cancer cells while protecting surrounding tissue and minimizing chances for erectile and urinary dysfunction associated with other treatments.

13 Oct 2015

SMC approves Bayer's Xofigo for treatment of castration-resistant prostate cancer in NHS Scotland

The Scottish Medicines Consortium has today announced that Xofigo has been accepted for use within NHS Scotland for the treatment of adult patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

13 Oct 2015

Men on effective HIV therapy less likely to get HBV infection, shows research

Previous studies of individuals with HIV have suggested that HIV drug regimens that included drugs active against hepatitis B virus (HBV) can decrease the risk of infection with the liver-damaging HBV.

13 Oct 2015

Prostate Cells Undergo 'Reprogramming' To Form Tumors, Study Finds

Scientists have gained a key insight into how prostate tumors get their start - not by rewriting the normal DNA code, but by reprogramming the master regulator of genes in prostate cells to drive malignant growth.

12 Oct 2015

Is dyspraxia a battle of the sexes?

New findings released Monday 12 October 2015 have revealed a significant gap in the diagnosis – and therefore, treatment – of dyspraxia, otherwise known as developmental co-ordination disorder (DCD), amongst young women and girls.

12 Oct 2015

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

OncoGenex Pharmaceuticals, Inc. announced today that the European Medicines Agency has completed its review of the proposed amendment to the company's Phase 3 AFFINITY protocol and statistical analysis plan.

8 Oct 2015

Study shows men and women react very differently to various types of infidelity

If your partner has sex with someone else, it is considered infidelity - even if no emotions are involved. But it is also considered infidelity when your significant other develops a close personal relationship with someone else, even if there is no sex or physical intimacy involved.

8 Oct 2015

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.

7 Oct 2015

Recipients of 2015 Ferring Innovation Grants announced

Ferring Research Institute Inc. today announced the recipients of the 2015 Ferring Innovation Grants. This global program awards each recipient $50,000 to support research in the fields of Reproductive Health, Gastroenterology and/or Urology.

7 Oct 2015

Researchers study effect of immune tolerance on certain cancer risks

For a malignant tumor to form, cancer cells must evade the immune system's attack. Numerous studies have already shown that cancer spreads particularly aggressively if there is an unfavorable balance between suppressing and active immune cells in the tumor microenvironment. "But we didn't know whether this is a consequence of an aggressive tumor or rather its cause," says Rudolf Kaaks, epidemiologist at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).

7 Oct 2015

Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with recurrent or metastatic castration resistant prostate cancer (IND 209). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario.

6 Oct 2015

First-time expectant dads experience depression

Transition to parenthood can be a difficult life event. It can have an impact on both parents and on the long-term development of the child. While mother's "baby blues" have been widely investigated, little research has been conducted on antenatal paternal depression. A team from the Research Institute of the McGill University Health Centre sheds light on fathers' mental health by releasing the first study to report the prevalence of antenatal depression symptoms among Canadian men.

6 Oct 2015

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

A new population-based study from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five-year period was not associated with an increased risk of aggressive prostate cancer. Further, risk of high-grade prostate cancer did not increase according to the total number of testosterone injections.

5 Oct 2015

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiveness after about one to two years, leading to recurrence and, ultimately, death. A University of Houston researcher and his team are working to change that.

30 Sep 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Age, race and family history are the biggest risk factors for prostate cancer, new research suggests

New research suggests that age, race and family history are the biggest risk factors for a man to develop prostate cancer, although high blood pressure, high cholesterol, vitamin D deficiency, inflammation of prostate, and vasectomy also add to the risk. In contrast, obesity, alcohol abuse, and smoking show a negative association with the disease.

30 Sep 2015

New global educational initiative helps men identify symptoms of advanced prostate cancer

Although prostate cancer may exhibit no symptoms in its early stages, symptoms like severe or unexplained pain, difficulty walking or climbing stairs, difficulty sleeping or loss of bladder control may emerge when the disease advances as a signal to men to take action with their doctors.

29 Sep 2015

Men's Health News

High Intensity Focused Ultrasound treatment now available in the U.S. to treat prostate cancer

SMC approves Bayer's Xofigo for treatment of castration-resistant prostate cancer in NHS Scotland

Men on effective HIV therapy less likely to get HBV infection, shows research

Prostate Cells Undergo 'Reprogramming' To Form Tumors, Study Finds

Is dyspraxia a battle of the sexes?

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

Study shows men and women react very differently to various types of infidelity

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Recipients of 2015 Ferring Innovation Grants announced

Researchers study effect of immune tolerance on certain cancer risks

Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

First-time expectant dads experience depression

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Age, race and family history are the biggest risk factors for prostate cancer, new research suggests

New global educational initiative helps men identify symptoms of advanced prostate cancer

New global educational initiative helps men identify symptoms of advanced prostate cancer

Fewer, higher doses of radiotherapy effective at treating prostate cancer

Fidgeting while sitting may be good for us

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News